09/27/23 5:45 PMNasdaq : BPTS low floatBiophytis Releases Its Half-Yearly Accounts as of 30 June 2023 and Provides an Update on Its OperationsStart of industrial development of Sarconeos (BIO101) with a view to market access in severe forms of Covid-19 (COVA)Approvals to start the Phase 3 trial in the United States and Belgium in sarcopenia (SARA), a world first, opening up the prospect of partnershipsCash position and secured financingRHEA-AIneutral
09/25/23 1:30 AMNasdaq : BPTS partnershiplow floatBiophytis and Skyepharma sign a Partnership Agreement for the Production of Sarconeos (BIO101)PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 25, 2023 / Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), (Biophytis), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated withRHEA-AIneutral
09/19/23 1:40 AMNasdaq : BPTS covid-19low floatBiophytis Provides an Update on its Early Access Programs for Sarconeos (BIO101) in the Treatment of Severe Forms of COVID-19PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 19, 2023 / Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), (Biophytis), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated withRHEA-AIneutral
09/14/23 1:30 AMNasdaq : BPTS managementlow floatBiophytis Strengthens its Management Team with the Appointment of its Chief Business OfficerPARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 14, 2023 / Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), (Biophytis), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated withRHEA-AIneutral
09/11/23 1:20 AMNasdaq : BPTS clinical triallow floatBiophytis Obtains FDA Authorization to Initiate the SARA-31 Phase 3 Study in SarcopeniaPARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 11,2023 / Biophytis SA (Nasdaq CM:BPTS)(Euronext Growth Paris:ALBPS), («Biophytis»), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processesRHEA-AIneutral
09/04/23 5:30 PMNasdaq : BPTS conferenceslow floatBiophytis to Participate at the H.C. Wainwright 25th Global Investment Conference in New YorkPARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 4, 2023 / Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing theRHEA-AIneutral
08/16/23 1:15 AMNasdaq : BPTS low floatBiophytis Announces Next Regulatory Steps in Europe and the United States for its COVA ProjectPARIS FRANCE and CAMBRIDGE, MA / ACCESSWIRE / August 16, 2023 / Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), ("Biophytis"), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associatedRHEA-AIneutral
08/08/23 1:20 AMNasdaq : BPTS clinical triallow floatBiophytis Receives a Positive Opinion for its SARA-31 Phase 3 Study in Sarcopenia in EuropePARIS, FRANCE / CAMBRIDGE, MA / ACCESSWIRE / August 8, 2023 / Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), ("Biophytis"), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associatedRHEA-AIneutral
07/20/23 1:20 AMNasdaq : BPTS acquisitioncovid-19low floatBiophytis has Requested a Pre-Submission Meeting with the FDA for an Emergency Use Authorization of Sarconeos (BIO101) for the Treatment of COVID-19PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / July 20, 2023 / Biophytis SA (Nasdaq CM:BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis"), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associatedRHEA-AIneutral
07/19/23 2:20 AMNasdaq : BPTS offeringlow floatBiophytis Announces $3.8 Million Registered Direct OfferingPARIS, FRANCE / CAMBRIDGE, MA / ACCESSWIRE / July 19, 2023 / Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerativeRHEA-AIneutral